Vactech Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 3

Vactech General Information

Description

Developer of vaccines and diagnostic technologies designed to focus on the treatment of diabetes and other immune-mediated diseases and enteroviruses. The company develops vaccines for human diseases like type 1 diabetes, celiac disease, asthma, and allergy, and diagnostics, enabling health institutions to get access to medical products that aid them in curing various immunity and virus-related diseases in patients.

Contact Information

Website
www.vactech.fi
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Biokatu 8
  • 33520 Tampere
  • Finland
+358 03
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • Biokatu 8
  • 33520 Tampere
  • Finland
+358 03

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vactech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 23-Jun-2016 Completed Clinical Trials - Phase 1
2. Later Stage VC 01-Jan-2011 Completed Clinical Trials - Phase 1
1. Later Stage VC 30-Sep-2009 Completed Clinical Trials - Phase 1
To view Vactech’s complete valuation and funding history, request access »

Vactech Patents

  • 55

    Total Documents Applications and Grants

  • Total Patents Families

  • 23

    Granted

  • 6

    Pending

  • Expiring in next 12 mo

Vactech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4422680-A1 Coxsackievirus b compositions and methods of use thereof Pending 25-Oct-2021
EP-4422680-A4 Coxsackievirus b compositions and methods of use thereof Pending 25-Oct-2021
US-20250352634-A1 Coxsackievirus b compositions and methods of use thereof Pending 25-Oct-2021
WO-2023076856-A1 Coxsackievirus b compositions and methods of use thereof Inactive 25-Oct-2021
JP-2024540976-A Group b coxsackievirus compositions and methods of use thereof Pending 25-Oct-2021 A61K39/125
To view Vactech’s complete patent history, request access »

Vactech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vactech Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Innovestor Venture Capital Minority
Tekes Not-For-Profit Venture Capital Minority
Finnvera Lender/Debt Provider Minority
To view Vactech’s complete investors history, request access »

Ready to get started?

Request a free trial

Vactech FAQs

  • When was Vactech founded?

    Vactech was founded in 2001.

  • Where is Vactech headquartered?

    Vactech is headquartered in Tampere, Finland.

  • What is the size of Vactech?

    Vactech has 11 total employees.

  • What industry is Vactech in?

    Vactech’s primary industry is Biotechnology.

  • Is Vactech a private or public company?

    Vactech is a Private company.

  • What is Vactech’s current revenue?

    The current revenue for Vactech is .

  • Who are Vactech’s investors?

    Innovestor, Tekes, and Finnvera have invested in Vactech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process